These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 22868187)

  • 1. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children.
    Espinosa-Padilla SE; Murata C; Estrada-Parra S; Santos-Argumedo L; Mascareñas C; Franco-Paredes C; Espinosa-Rosales FJ
    Arch Med Res; 2012 Jul; 43(5):402-5. PubMed ID: 22868187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
    Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
    Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.
    Frenck R; Thompson A; Yeh SH; London A; Sidhu MS; Patterson S; Gruber WC; Emini EA; Scott DA; Gurtman A;
    Pediatr Infect Dis J; 2011 Dec; 30(12):1086-91. PubMed ID: 21983216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
    Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
    Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term Polish infants.
    Szynczewska E; Chlebna-Sokół D
    Vaccine; 2011 Sep; 29(40):7107-13. PubMed ID: 21803093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal polysaccharide immunization in infants and children.
    Cowan MJ; Ammann AJ; Wara DW; Howie VM; Schultz L; Doyle N; Kaplan M
    Pediatrics; 1978 Nov; 62(5):721-7. PubMed ID: 31592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination.
    Holmlund E; Nohynek H; Quiambao B; Ollgren J; Käyhty H
    Vaccine; 2011 Jun; 29(28):4565-75. PubMed ID: 21550374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of pneumococcal vaccine in heart transplant recipients.
    Blumberg EA; Brozena SC; Stutman P; Wood D; Phan HM; Musher DM
    Clin Infect Dis; 2001 Jan; 32(2):307-10. PubMed ID: 11170924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An immunoenzymatic test for IgG antibody levels against 10 serotypes of Streptococcus pneumoniae].
    Leal-Esteban LC; Rojas JL; Jaimes AL; Montoya JD; Montoya NE; Leiva L; Trujillo-Vargas CM
    Biomedica; 2012; 32(1):92-102. PubMed ID: 23235791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.